These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22033247)

  • 1. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.
    Delang L; Froeyen M; Herdewijn P; Neyts J
    Antiviral Res; 2012 Jan; 93(1):30-8. PubMed ID: 22033247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
    Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
    Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.
    Howe AY; Cheng H; Thompson I; Chunduru SK; Herrmann S; O'Connell J; Agarwal A; Chopra R; Del Vecchio AM
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4103-13. PubMed ID: 16940072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
    Mo H; Lu L; Pilot-Matias T; Pithawalla R; Mondal R; Masse S; Dekhtyar T; Ng T; Koev G; Stoll V; Stewart KD; Pratt J; Donner P; Rockway T; Maring C; Molla A
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4305-14. PubMed ID: 16189112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted 2,6-bis(benzimidazol-2-yl)pyridines: a novel chemical class of pestivirus inhibitors that targets a hot spot for inhibition of pestivirus replication in the RNA-dependent RNA polymerase.
    Musiu S; Pürstinger G; Stallinger S; Vrancken R; Haegeman A; Koenen F; Leyssen P; Froeyen M; Neyts J; Paeshuyse J
    Antiviral Res; 2014 Jun; 106():71-9. PubMed ID: 24680957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.
    Tomei L; Altamura S; Bartholomew L; Bisbocci M; Bailey C; Bosserman M; Cellucci A; Forte E; Incitti I; Orsatti L; Koch U; De Francesco R; Olsen DB; Carroll SS; Migliaccio G
    J Virol; 2004 Jan; 78(2):938-46. PubMed ID: 14694125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
    Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replication of a novel subgenomic HCV genotype 1a replicon expressing a puromycin resistance gene in Huh-7 cells.
    Liang C; Rieder E; Hahm B; Jang SK; Paul A; Wimmer E
    Virology; 2005 Mar; 333(1):41-53. PubMed ID: 15708591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.
    Pawlotsky JM; Najera I; Jacobson I
    Antivir Ther; 2012; 17(3):411-23. PubMed ID: 22402762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
    Shi ST; Herlihy KJ; Graham JP; Fuhrman SA; Doan C; Parge H; Hickey M; Gao J; Yu X; Chau F; Gonzalez J; Li H; Lewis C; Patick AK; Duggal R
    Antimicrob Agents Chemother; 2008 Feb; 52(2):675-83. PubMed ID: 18070954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
    Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
    Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate.
    Slater MJ; Amphlett EM; Andrews DM; Bravi G; Burton G; Cheasty AG; Corfield JA; Ellis MR; Fenwick RH; Fernandes S; Guidetti R; Haigh D; Hartley CD; Howes PD; Jackson DL; Jarvest RL; Lovegrove VL; Medhurst KJ; Parry NR; Price H; Shah P; Singh OM; Stocker R; Thommes P; Wilkinson C; Wonacott A
    J Med Chem; 2007 Mar; 50(5):897-900. PubMed ID: 17269759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibitors of hepatitis C virus replication.
    Neyts J
    Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase.
    Paeshuyse J; Letellier C; Froeyen M; Dutartre H; Vrancken R; Canard B; De Clercq E; Gueiffier A; Teulade JC; Herdewijn P; Puerstinger G; Koenen F; Kerkhofs P; Baraldi PG; Neyts J
    Antiviral Res; 2009 Jun; 82(3):141-7. PubMed ID: 19428605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors.
    Rydberg EH; Cellucci A; Bartholomew L; Mattu M; Barbato G; Ludmerer SW; Graham DJ; Altamura S; Paonessa G; De Francesco R; Migliaccio G; Carfí A
    J Mol Biol; 2009 Jul; 390(5):1048-59. PubMed ID: 19505479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.